Physician profile
Haoli Jin
NPI 1700182300
$2,149.53
in general payments reported to CMS, 2019-2025
9 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $35.82 · 2021: $30.47 · 2022: $110 · 2023: $400 · 2024: $898 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.70 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $644.18 | 2022-2024 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $541.51 | 2024-2025 | Fasenra, Breztri |
| Genentech USA, INC. | $352.75 | 2019-2025 | Xolair |
| Shire North American Group INC | $125.00 | 2019 | |
| Genzyme Corporation | $123.83 | 2024 | |
| Glaxosmithkline, LLC. | $120.64 | 2024 | Nucala |
| Pharming Healthcare, INC. | $100.33 | 2023 | Ruconest |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Alk-Abello, INC | $66.29 | 2020-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haoli Jin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.